| MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. | leukemia, |
| Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. | None |
| The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. | None |
| B-cell development in the presence of the MLL/AF4 oncoprotein proceeds in the absence of HOX A7 and HOX A9 expression. | None |
| The small oligomerization domain of gephyrin converts MLL to an oncogene. | None |
| Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. | None |
| the CXXC DNA binding domain has a critical role in MLL-associated oncogenesis, most likely via epigenetic recognition of CpG DNA sites within the regulatory elements of target genes | None |
| Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. | None |
| A permissive cellular environment is required for oncogenicity of Mll-associated translocations and Mll fusions can influence haematopoietic lineage commitment. | None |
| pharmacological, physiological and genetic studies that demonstrate an oncogenic requirement for GSK3 in the maintenance of a specific subtype of poor prognosis human leukaemia, genetically defined by mutations of the MLL proto-oncogene | None |
| DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. | None |
| A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. | None |
| Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. | None |
| Ras activation seems to complement the MLLT3-MLL oncogene in transformation. | None |
| [Acute myeloblastic leukaemia with alternations of MLL proto-oncogene protein (11q23/MLL+ AML)]. | None |
| Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. | None |
| MLL translocations relieve oncogenic MLL-PG fusions from the repressive MLL 3_UTR, contributing to higher activity of these genes and leukaemia development | None |
| IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. | None |
| Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. | None |
| Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death. | None |